ALK inhibitors like lorlatinib, a third-generation TKI with effective central nervous system (CNS) penetration, have shown substantial efficacy in managing ALK-positive NSCLC, especially in cases with brain metastases (BMs) (Tao et al., 2022). Here, ALK is linked to burning mouth syndrome.